Eisai initiates submission of application data of lecanemab under the prior assessment consultation system in Japan with the aim of an earlier regulatory approval
Hits: 574
LUND, Sweden I March 1, 2021 I Oncorena, dedicated to developing a unique and potential breakthrough therapy for metastatic renal cancer, today announces the Swedish Medical Products Agency s approval of the Phase 1/2 of First in Patient trial of the first-in-class compound, orellanine in patients with metastatic renal cancer in dialysis.
Preclinical evidence shows that orellanine, a well known fungus toxin, specifically exerts powerful anti-tumor effects on metastatic renal cancer in different preclinical models. Orellanine has a unique mode of action. All preclinical activities have been completed and the Swedish Medical Products Agency has approved Oncorena s first clinical trial in patients with metastatic renal cancer on dialysis.